spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  solid tumor 


 Your search returned too many results! The most recent 500 items are shown below:
 HSMN NewsFeed - 13 Jul 2026
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier(R)
Devices Oncology
 HSMN NewsFeed - 20 May 2026
Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 11 May 2026
Partner Therapeutics Announces FDA Approval of BIZENGRI(R) (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2026
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 May 2026
Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
Devices Oncology
 HSMN NewsFeed - 13 Apr 2026
Lilly's Jaypirca (Pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2026
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2026
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Feb 2026
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Nov 2025
New Study Shows Aliya(R) Pulsed Electric Field Ablation Achieved Local Control of Lung Tumors in Metastatic Cancer Patients and May Induce an Immune Response
Devices Oncology
 HSMN NewsFeed - 4 Nov 2025
Ratio Therapeutics Announces the Appointment of Marcel Reichen as Chief Strategy Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Oct 2025
CAPS Medical's PlasmaSure(TM) Receives FDA Breakthrough Device Designation
Devices Oncology FDA
 HSMN NewsFeed - 2 Sep 2025
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 5 Aug 2025
Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2025
Tract Bio Appoints Chris Galloway, M.D., as Chief Medical and Development Officer and Expands Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2025
Sanofi to Acquire Blueprint Medicines, Expanding Portfolio in Rare Immunological Disease and Adding Early-stage Pipeline in Immunology
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 May 2025
Neutron Therapeutics and Helsinki University Hospital Treat First Head and Neck Cancer Patients Using Accelerator-Based Boron Neutron Capture Therapy
Devices Oncology
 HSMN NewsFeed - 15 May 2025
Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy
Devices Oncology Venture Capital
 HSMN NewsFeed - 7 May 2025
PAQ Therapeutics Announces $39 Million Series B Financing and Initiates Phase 1 Trial to Advance Novel Approach Addressing KRAS-Driven Cancers with High Unmet Need
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Mar 2025
Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathway
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Feb 2025
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Dec 2024
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 26 Nov 2024
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Nov 2024
SOPHiA GENETICS Launches MSK-IMPACT(R) powered with SOPHiA DDM(TM) at AMP 2024
Diagnostics Product Launch
 HSMN NewsFeed - 1 Nov 2024
CARsgen(R) U.S. Clinical Holds Lifted by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Oct 2024
Pillar Biosciences Receives CPT(R) Code for FDA Approved oncoReveal(TM) CDx Pan-Cancer Solid tumor IVD Kit
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 24 Oct 2024
Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Oct 2024
Alphina Therapeutics Appoints Veteran Biotech Executive, Nick Galli, as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Sep 2024
Aktis Oncology Announces $175 Million Oversubscribed Series B Financing to Further Advance its Proprietary Radiopharmaceutical Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jun 2024
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 May 2024
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 May 2024
SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 May 2024
Compugen Appoints David Silberman as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 May 2024
Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Apr 2024
SystImmune, Inc. Appoints Dr. Jie D'Elia as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Apr 2024
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Apr 2024
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 5 Apr 2024
Labcorp Launches Labcorp(R) Plasma Detect(TM) Extending Leadership into Molecular Residual Disease (MRD) Clinical Research
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 2 Apr 2024
NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Mar 2024
Nested Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NST-628, a Novel Pan-RAF/MEK Molecular Glue
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Mar 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 28 Feb 2024
Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Feb 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Feb 2024
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Feb 2024
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Feb 2024
ProfoundBio Raises $112 Million in Oversubscribed Series B Equity Financing to Advance its Clinical-Stage Antibody-Drug Conjugate (ADC) Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Feb 2024
AbbVie Completes Acquisition of ImmunoGen
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 17 Jan 2024
Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 15 Jan 2024
NeoImmuneTech Welcomes a New President for its Development and Business
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Dec 2023
cTRL Therapeutics Appoints Ruben Rodriguez, Ph.D., as Head of Research
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Nov 2023
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Nov 2023
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Nov 2023
Actinium Appoints Lynn Bodarky as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Nov 2023
cTRL Therapeutics Appoints Derrell D. Porter, M.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Sep 2023
Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Aug 2023
Zumutor Biologics Inc Announces FDA Clearance of IND Application of ZM008, a Novel Monoclonal Antibody Drug Against Multiple Solid Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2023
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2023
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Jun 2023
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Jun 2023
Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jun 2023
VA Oklahoma City Healthcare System Chooses ViewRay's MRIdian(R) MRI-Guided Radiation Therapy System
Devices Oncology
 HSMN NewsFeed - 6 Jun 2023
Acepodia Secures $100 Million Series D Financing to Advance
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 May 2023
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 25 Apr 2023
Strata Oncology Announces Launch and Medicare Coverage for Strata Select, a First-of-its-kind Immunotherapy Test
Diagnostics Oncology Product Launch Reimbursement
 HSMN NewsFeed - 3 Mar 2023
Aadi Bioscience Announces Leadership Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Mar 2023
Siteman Cancer Center at Washington University Treats 2,000th Patient with MRIdian(R) MRI-Guided Radiation Therapy
Devices Oncology
 HSMN NewsFeed - 28 Feb 2023
Verismo Therapeutics Announces $7 Million Pre-Series A with BRV Capital Management as Lead Investor
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Feb 2023
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Feb 2023
Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 9 Jan 2023
Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Dec 2022
STORM Therapeutics announces closing of USD $30M Series B financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 6 Dec 2022
Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy
Diagnostics Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2022
Haystack Oncology Launches with $56 Million in Series A Financing to Accelerate Adoption of Post-Op Cancer Detection Technology and Optimize Cancer Therapy Monitoring and Treatment
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Oct 2022
ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients
Devices Oncology
 HSMN NewsFeed - 21 Sep 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Sep 2022
MD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy Program
Devices Oncology
 HSMN NewsFeed - 16 Sep 2022
Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2022
Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Sep 2022
GenesisCare Purchases Two Additional ViewRay MRIdian MRI-guided Radiotherapy Systems for Guildford and Birmingham Projects, Doubling United Kingdom Footprint to Four Systems
Devices Oncology
 HSMN NewsFeed - 7 Sep 2022
ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients
Devices Oncology Regulatory
 HSMN NewsFeed - 7 Sep 2022
STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Aug 2022
3T Biosciences Debuts with $40 Million Series A Financing
Biopharmaceuticals Oncology Personnel Venture Capital
 HSMN NewsFeed - 24 Aug 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2022
VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
Devices Oncology
 HSMN NewsFeed - 19 Aug 2022
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jul 2022
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Jul 2022
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jul 2022
Saitama Medical University International Medical Center Selects MRIdian(R) MRI-Guided Radiation Therapy System
Devices Oncology
 HSMN NewsFeed - 13 Jul 2022
Immunitas Therapeutics Appoints Lynette Herscha as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Jun 2022
VA Ann Arbor Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
Devices Oncology
 HSMN NewsFeed - 7 Jun 2022
Shin-Matsudo Central General Hospital Select's ViewRay's MRIdian(R) MRI-Guided Radiation Therapy System to Expand Access to Precision Radiation Therapy
Devices Oncology
 HSMN NewsFeed - 2 Jun 2022
Henry Ford Health Becomes the First Center to Treat Patients with ViewRay's MRIdian A3i System
Devices Oncology
 HSMN NewsFeed - 31 May 2022
Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 May 2022
UCI Health Adopts ViewRay(R) MRIdian(R) MRI-Guided Radiation Therapy System
Devices Oncology
 HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Mar 2022
Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Mar 2022
TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Mar 2022
University Hospital Agostino Gemelli Treats its 1,000th Patient Using MRIdian(R) MRI-Guided Radiation Therapy
Devices Oncology
 HSMN NewsFeed - 14 Mar 2022
Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation from the FDA for the Treatment of T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Mar 2022
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Feb 2022
TC Biopharm Announces Appointment of New Board Members
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Feb 2022
Bexion Pharmaceuticals Announces Leadership Additions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jan 2022
Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
Devices Oncology
 HSMN NewsFeed - 17 Jan 2022
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jan 2022
Jens Lindberg takes office as CEO of Medivir on January 24
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jan 2022
SK Life Science Announces FDA Clearance of IND Application for its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 10 Jan 2022
Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT(TM) in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events
Devices Oncology
 HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2022
Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
Devices Oncology
 HSMN NewsFeed - 15 Dec 2021
ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features
Devices Oncology FDA
 HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2021
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Dec 2021
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Nov 2021
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2021
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 24 Nov 2021
ViewRay Announces MRIdian MR-Guided Radiation Therapy Surpasses 2,300 Pancreatic Cancer Patients Treated Worldwide
Devices Oncology
 HSMN NewsFeed - 11 Nov 2021
Actym Therapeutics Appoints Chan Whiting as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Nov 2021
Ichnos Sciences Appoints Sonia Quaratino, M.D., Ph.D., To Its Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Nov 2021
Kintara Announces Changes to Executive Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Nov 2021
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Oct 2021
BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Oct 2021
Helsinki University Hospital Selects MRIdian(R) System for Installation at Comprehensive Cancer Center
Devices Oncology
 HSMN NewsFeed - 25 Oct 2021
Medivir Appoints Jens Lindberg as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2021
Targovax ASA appoints Dr. Erik Digman Wiklund as new CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Oct 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
Devices Oncology FDA
 HSMN NewsFeed - 7 Oct 2021
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Sep 2021
Japan's MHLW Approves PADCEV(R) (enfortumab vedotin) for Advanced Urothelial Cancer
Biopharmaceuticals Urology Oncology Regulatory
 HSMN NewsFeed - 22 Sep 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Sep 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Sep 2021
RenovoRx Receives New 510(k) Clearance for its RenovoCath(R) Delivery System Designed for Targeted Treatment of Solid Tumors
Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 23 Aug 2021
Lightpoint Medical and Telix Pharmaceuticals Announce Strategic Collaboration Agreement
Devices Radiology Oncology
 HSMN NewsFeed - 18 Aug 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Aug 2021
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jul 2021
Strata Oncology Completes $90 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Jul 2021
Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2021
Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jul 2021
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jul 2021
Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2021
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Jun 2021
Cardinal Health(TM) Nuclear & Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK(R) Pediatric Indication
Biopharmaceuticals Radiology Oncology FDA
 HSMN NewsFeed - 9 Jun 2021
Lightpoint Medical Expands Executive Leadership Team with Appointment of Graeme Smith to CEO
Devices Personnel
 HSMN NewsFeed - 8 Jun 2021
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2021
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 20 May 2021
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 17 May 2021
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 May 2021
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 11 May 2021
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 5 May 2021
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 3 May 2021
Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Apr 2021
Medivir appoints Magnus Christensen as interim CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Apr 2021
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse(TM)" for the Treatment of Solid Tumors
Devices Oncology Regulatory
 HSMN NewsFeed - 8 Apr 2021
Imvax Appoints Sean Hemingway as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Apr 2021
FDA Grants Breakthrough Therapy Designation for Taiho Oncology's Futibatinib for Treatment of Advanced Cholangiocarcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Mar 2021
Lightpoint Medical Announces $8 Million in Funding to Support Commercial Launch of its Robotic Cancer Detection Probe
Devices Oncology Venture Capital
 HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Mar 2021
Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 17 Mar 2021
Codagenix Expands Senior Management Team With Three New Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Mar 2021
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Mar 2021
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Mar 2021
PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Feb 2021
Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Feb 2021
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 11 Feb 2021
Penn State Health Purchases Second ViewRay MRIdian(R) Linac
Devices Radiology Oncology
 HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 26 Jan 2021
The Henry Ford Cancer Institute Installs its Second ViewRay MRIdian(R) Linac
Devices Oncology
 HSMN NewsFeed - 18 Jan 2021
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jan 2021
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 31 Dec 2020
ImmVira Announces Series C Financing with Leading Specialist Investors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 Dec 2020
Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea(R) (Paclitaxel Micellar) in Europe
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 Dec 2020
Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2020
Servier to Acquire Agios Pharmaceuticals' Oncology Business
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 8 Dec 2020
Amgen's Sotorasib Granted Breakthrough Therapy Designation for Advanced or Metastatic Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2020
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 18 Nov 2020
Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunotherapy Platform
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Nov 2020
Discovery Life Sciences Launches TruSight Oncology 500 (TSO500) Solid Tumor FFPE and cfDNA Services to Advance Liquid Biopsy Development and Immunotherapy Clinical Research
Diagnostics Product Launch
 HSMN NewsFeed - 2 Nov 2020
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Oct 2020
Steven Yecies Joins Javelin Oncology as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Oct 2020
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Biopharmaceuticals Licensing Acquisitions
 HSMN NewsFeed - 14 Oct 2020
Louis Stokes Cleveland VA Medical Center Purchases ViewRay's MRIdian Linac for MRI-Guided Radiation Therapy
Devices Oncology
 HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Sep 2020
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 9 Sep 2020
Phosplatin Therapeutics Announces Two Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Sep 2020
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Sep 2020
10,000th Patient Receives Treatment with ViewRay's MRIdian System
Devices Radiology Oncology
 HSMN NewsFeed - 25 Aug 2020
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Aug 2020
Kintara Therapeutics (Formerly DelMar Pharmaceuticals) Announces Completion of Merger with Adgero Biopharmaceuticals and Closing of $19.6 Million Private Placement Priced At-The-Market
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 18 Aug 2020
ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 17 Aug 2020
DelMar Announces Approval of Merger by Stockholders
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 13 Aug 2020
Dartmouth-Hitchcock Health Begins Patient Treatments with ViewRay's MRIdian Linac
Devices Radiology Oncology
 HSMN NewsFeed - 27 Jul 2020
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jul 2020
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 16 Jul 2020
Imvax Inc. Raises $112 Million in Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 8 Jul 2020
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Jul 2020
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 25 Jun 2020
Poseida Therapeutics Raises $110 Million in Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Jun 2020
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
Diagnostics Oncology Mergers & Acquisitions
 HSMN NewsFeed - 16 Jun 2020
EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jun 2020
Alpha Tau Medical Announces Successful Completion of New $26 Million Funding Round
Devices Oncology Venture Capital
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 May 2020
Providence Portland Medical Center Begins Patient Treatments with ViewRay's MRIdian Linac
Devices Oncology
 HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 May 2020
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 19 May 2020
BioEclipse Therapeutics(TM) Announces Move to New Corporate Headquarters in Mountain View, CA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2020
ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions
Diagnostics Oncology FDA
 HSMN NewsFeed - 11 May 2020
Jazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2020
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Apr 2020
Actym Therapeutics Raises $34 Million Series A
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 20 Apr 2020
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector(TM) Technology Validated for Use in Both Tissue and Blood Samples
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Apr 2020
Bolt Biotherapeutics Appoints Edith Perez, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Apr 2020
Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Apr 2020
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2020
Elevar Therapeutics Acquires Global Rights to European Approved Apealea(R) from Oasmia Pharmaceutical
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2020
F1 Oncology Changes Name To EXUMA Biotech; Announces New Round Of Financing To Advance Cellular Therapies
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 25 Feb 2020
KAHR Medical Raises $18 Million in Private Funding Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Jan 2020
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jan 2020
Candel Therapeutics Appoints Sandra E. Poole as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jan 2020
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jan 2020
Revitope Oncology Appoints Steve Arkinstall, D.Phil., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jan 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jan 2020
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 26 Dec 2019
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Dec 2019
Michigan Community Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
Devices Oncology
 HSMN NewsFeed - 17 Dec 2019
ArcherDX Announces Close of $55 Million Series C Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 16 Dec 2019
Anixa Biosciences Announces Commercial Launch of Cchek(TM) Prostate Cancer Confirmatory Test
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 10 Dec 2019
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2019
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Nov 2019
Anixa Biosciences Announces Collaboration with Urology Centers of Alabama on Cchek(TM) Prostate Cancer Study
Diagnostics Urology Oncology
 HSMN NewsFeed - 21 Nov 2019
Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 5 Nov 2019
A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A To Develop A Pipeline Of Selective Tumor Cell Therapeutics
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 31 Oct 2019
Cytotron(R) Granted 'Breakthrough Device Designation' by U.S. FDA for Treatment of Breast, Liver, and Pancreatic Cancers
Devices Oncology FDA
 HSMN NewsFeed - 30 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 28 Oct 2019
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Oct 2019
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 15 Oct 2019
Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts
Diagnostics Oncology Personnel
 HSMN NewsFeed - 16 Sep 2019
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Sep 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Sep 2019
NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Aug 2019
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2019
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Aug 2019
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 22 Aug 2019
Torque Expands Leadership Team with Appointment of Sok Cheng Soh as CFO and Ana Radeljevic as VP, Head of Business Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Aug 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jul 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX(R) Utilizing ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery Regulatory
 HSMN NewsFeed - 17 Jul 2019
Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 9 Jul 2019
IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Jul 2019
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Jun 2019
Dignitana receives FDA clearance for DigniCap Delta scalp cooling system
Devices FDA
 HSMN NewsFeed - 24 Jun 2019
BioEclipse Therapeutics(TM) Announces Appointment of New Directors and Series A-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 18 Jun 2019
FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jun 2019
Pfizer to Acquire Array BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Jun 2019
Carisma Therapeutics Names Dr. Robert Petit as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 May 2019
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2019
Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel Molecular Intelligence (MI) Transcriptome(TM)
Diagnostics Oncology
 HSMN NewsFeed - 22 May 2019
Halozyme Announces argenx Has Selected Second Target Under ENHANZE(R) Technology Collaboration And License Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 21 May 2019
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 May 2019
Caris Life Sciences Receives FDA Breakthrough Device Designation for MI Transcriptome(TM) Companion Diagnostic Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 16 Apr 2019
Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Apr 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Apr 2019
Petra Pharma Strengthens Management Team with Recent Leadership Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Mar 2019
Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Mar 2019
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Biopharmaceuticals Urology Oncology
 HSMN NewsFeed - 25 Mar 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Mar 2019
Petra Pharma announces licensing agreement with Takeda Pharmaceutical Company
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Mar 2019
ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth
Diagnostics Personnel
 HSMN NewsFeed - 1 Mar 2019
Rakuten Aspyrian Announces Name Change to Rakuten Medical
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Feb 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 26 Feb 2019
NW Bio Hires David Innes As Vice President, Investor Relations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Feb 2019
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Feb 2019
Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Feb 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 23 Jan 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jan 2019
European Commission Approves BLINCYTO(R) (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Dec 2018
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Dec 2018
Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Nov 2018
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Nov 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2018
Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Oct 2018
Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek(TM) Cancer Diagnostic Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 17 Oct 2018
Adam Hacker, PhD Joins Autolus as Senior Vice President for Regulatory Affairs and Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Oct 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2018
Medivir to Focus on its Clinical Development and Appoints Uli Hacksell as Acting CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Sep 2018
ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 19 Sep 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2018
ORIC Pharmaceuticals Appoints Pratik Multani, MD, as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Sep 2018
Targovax Strengthens Management Team With the Appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2018
Halozyme Appoints Bernadette Connaughton To Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2018
BioAtla Appoints Scott Smith As President
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2018
Halozyme Names Benjamin Hickey As Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2018
Israeli MedTech Start-up, Alpha Tau Medical, Raises $29 Million in Private Financing to Cure Cancer
Devices Radiology Oncology Venture Capital
 HSMN NewsFeed - 4 Sep 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 29 Aug 2018
European Commission Approves BLINCYTO(R) (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Aug 2018
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Aug 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Aug 2018
Rakuten Aspyrian Raises $150 Million in Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 21 Aug 2018
Alpha Tau's High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United States
Devices Oncology Regulatory
 HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Aug 2018
SQZ Biotech Completes Oversubscribed $72 Million Series C Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 8 Aug 2018
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX(R) (daratumumab) Split Dosing Regimen
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 25 Jul 2018
Torque Appoints James Mullen as Chairman of Board of Directors, Maykin Ho, PhD, as Strategic Advisor to the Board of Directors, and Mario Sznol, MD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jul 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jul 2018
ITUS Corporation Announces Second Commercial Focus for Cchek(TM) will be Breast Cancer
Diagnostics Oncology
 HSMN NewsFeed - 5 Jul 2018
Adlai Nortye Raises $53M in Series B
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Jul 2018
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Jun 2018
Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2018
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2018
AIVITA Biomedical Announces U.S. Food and Drug Administration Clearance of IND for Phase II Glioblastoma Multiforme Trial
Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 14 Jun 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jun 2018
Vergent Bioscience Raises $8.7 Million in Series A Financing Led by Spring Mountain Capital
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 11 Jun 2018
Replimune Appoints Dr. Hyam I. Levitsky to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 31 May 2018
Curis Announces FDA Fast Track Designation for Fimepinostat Development in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2018
Circulating Tumor Cells To Help Stage Metastatic Breast Cancer, New Research To Be Featured at ASCO Annual Meeting
Diagnostics Oncology
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 May 2018
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 May 2018
Immunicom's Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer
Devices Oncology FDA
 HSMN NewsFeed - 14 May 2018
Lilly to Acquire AurKa Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 10 May 2018
Lilly Announces Agreement To Acquire ARMO BioSciences
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 May 2018
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 30 Apr 2018
Forty Seven Inc. Appoints Ian T. Clark to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Apr 2018
MaxCyte Appoints Dr. Claudio Dansky Ullmann as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Apr 2018
Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Apr 2018
TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Apr 2018
Cumberland Pharmaceuticals Expands into Oncology Support
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 26 Mar 2018
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Mar 2018
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin(R)) For The Treatment Of Three Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Mar 2018
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Mar 2018
Torque Appoints John Hohneker, MD, to Board of Directors and Marcela Maus, MD, PhD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Mar 2018
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Feb 2018
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Feb 2018
Arterys Receives First FDA Clearance for Broad Oncology Imaging Suite with Deep Learning
Devices Radiology Oncology FDA
 HSMN NewsFeed - 5 Feb 2018
Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2018
RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2018
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Dec 2017
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Dec 2017
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 25 Dec 2017
I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Dec 2017
DARZALEX(R) (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2017
Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Nov 2017
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Oct 2017
OncoSec Presents Positive Phase 2 Data for ImmunoPulse(R) IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Sep 2017
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Sep 2017
Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 5 Sep 2017
Biocept Launches Liquid Biopsy Test for NRAS Mutations
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Aug 2017
MaxCyte Appoints Executive Vice President of Global Marketing
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Aug 2017
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
Diagnostics Product Launch
 HSMN NewsFeed - 31 Jul 2017
Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2017
Biocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 13 Jul 2017
American Society for Radiation Oncology Updates Insurance Coverage Recommendations for Proton Therapy
Devices Oncology
 HSMN NewsFeed - 11 Jul 2017
DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Jul 2017
Anaeropharma Science Announces Closing of Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Jul 2017
FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy
Devices Oncology FDA
 HSMN NewsFeed - 29 Jun 2017
Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe
Diagnostics Product Launch
 HSMN NewsFeed - 28 Jun 2017
Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2017
Churchill Pharmaceuticals Expands Commercial Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 May 2017
Biotheranostics Appoints Don Hardison as New CEO
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 15 May 2017
Formation Biologics Announces Dosing of First Patient in a Phase I/IIa Trial of AVID100, Closing of Series B Financing, and Appointment of Dr. Anthony Tolcher to its Board of Directors
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Apr 2017
Sorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 19 Apr 2017
Advaxis Appoints Anthony Lombardo as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Apr 2017
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 3 Apr 2017
Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch
 HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Mar 2017
Izun Pharmaceuticals Announces Approval of Curasite(TM) Hydrogel Wound Care Product by FDA
Biopharmaceuticals Wound Care FDA
 HSMN NewsFeed - 2 Mar 2017
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Feb 2017
Xynomic Pharma Has Acquired Worldwide Rights of Abexinostat
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 21 Feb 2017
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2017
DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test - ColoScape(TM) Real-Time PCR Kit
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 8 Feb 2017
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jan 2017
Ampersand Capital Partners and 1315 Capital to Acquire Genoptix
Diagnostics Oncology Mergers & Acquisitions
 HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2017
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jan 2017
Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Dec 2016
Provectus Biopharmaceuticals Terminates Peter Culpepper as Interim CEO and COO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2016
Foundation Medicine Receives FDA Approval of FoundationFocus(TM) CDxBRCA as a Companion Diagnostic for Rubraca(TM) (rucaparib) for the Treatment of Women with Ovarian Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 19 Dec 2016
Northern Biologics, Mosaic Biomedicals Execute Transformative Deal
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2016
Panther Biotechnology Receives Positive Feedback from the FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Nov 2016
Macrocure Announces New Date for Special General Meeting of Shareholders to Approve Merger With Leap Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 22 Nov 2016
DARZALEX(R) (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Nov 2016
Sorrento Therapeutics Closes Acquisition of Scilex
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 28 Oct 2016
Astellas to Acquire Ganymed Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Oct 2016
Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer
Diagnostics Oncology Personnel
 HSMN NewsFeed - 19 Oct 2016
SELLAS(TM) Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Oct 2016
Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Sep 2016
BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Aug 2016
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
Biopharmaceuticals Wound Care Mergers & Acquisitions
 HSMN NewsFeed - 17 Aug 2016
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Aug 2016
Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Aug 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Aug 2016
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Aug 2016
Sorrento Therapeutics Announces the Appointment of Dr. Yue Alexander Wu to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Jul 2016
NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
Devices Oncology
 HSMN NewsFeed - 13 Jul 2016
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2016
Advaxis Appoints Ranya Dajani as Vice President, Corporate Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jul 2016
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2016
IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Jun 2016
AiVita Biomedical Raises $2m in Series A Financing for Commercial and Clinical-Stage Program Development
Regenerative Medicine Venture Capital Personnel
 HSMN NewsFeed - 1 Jun 2016
Oncternal Therapeutics Merges with Tokalas to Form Clinical-Stage Biotechnology Company with Promising Oncology Pipeline
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 20 May 2016
Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 May 2016
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
Biopharmaceuticals Licensing Acquisitions
 HSMN NewsFeed - 13 May 2016
WaferGen Bio-systems and Takara Bio Inc. Announce Merger Agreement
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 May 2016
Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Apr 2016
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA
 HSMN NewsFeed - 6 Apr 2016
Sorrento Appoints Kevin M. Herde As Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Mar 2016
Curis Announces Expansion of Executive Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Mar 2016
Threshold Pharmaceuticals Appoints Stew Kroll as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Mar 2016
Huya Bioscience International Expands Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Feb 2016
CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing
 HSMN NewsFeed - 19 Feb 2016
eFFECTOR Therapeutics Increases its Series B Financing Round to $56M
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 11 Feb 2016
Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2016
Inivata Completes £31.5 Million ($45M) Series A Fundraising Round
Diagnostics Personalized Medicine Venture Capital
 HSMN NewsFeed - 25 Jan 2016
CARsgen Therapeutics Completes $30 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 25 Jan 2016
Steba Biotech Completes its European Phase 3 Clinical Trial of TOOKAD(R) in Patients with Low-Risk Prostate Cancer and Submits Marketing Authorization Application to the European Medicine Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 11 Jan 2016
Iconic Therapeutics Closes Series C Financing With New and Existing Investors
Biopharmaceuticals Oncology Ophthalmology Venture Capital
 HSMN NewsFeed - 11 Jan 2016
Tensha Therapeutics To Be Acquired By Roche
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 7 Jan 2016
Guardant Health Secures Series D Financing to Expand the Reach of its Digital Sequencing(TM) Platform in Oncology
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 1 Jan 2016
Lattice Biologics Completes Merger With Blackstone Ventures
Devices Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 22 Dec 2015
eFFECTOR Therapeutics Raises $40 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 500

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 500 additional stories matching:
solid tumor
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!